Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer
The purpose of this study was to compare the performance of 18F-FAPI PET/CT and 18F-FDG PET/CT in systemic staging of newly diagnosed breast cancer. Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both 18F-FAPI and 18F-FDG PET/CT from June 2022 to June 202...
Gespeichert in:
| Veröffentlicht in: | Academic radiology 2025-01, Vol.32 (1), p.50-57 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 57 |
|---|---|
| container_issue | 1 |
| container_start_page | 50 |
| container_title | Academic radiology |
| container_volume | 32 |
| creator | Bin, Ji Wenjia, Li Wan, Wang Kaiyin, Min Bowen, Yang Qichang, Wan Junzhi, Liu Shi, Gao |
| description | The purpose of this study was to compare the performance of 18F-FAPI PET/CT and 18F-FDG PET/CT in systemic staging of newly diagnosed breast cancer.
Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both 18F-FAPI and 18F-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard.
38 patients were included. The overall upstaging rate was 47.4% for 18F-FAPI PET/CT (18/38) and 34.2% for 18F-FDG PET/CT (13/38). The rate of distant metastases disclosed by 18F-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly different from that of 18F-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly higher than that of 18F-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P |
| doi_str_mv | 10.1016/j.acra.2024.07.058 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3101795322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1076633224005634</els_id><sourcerecordid>3101795322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1292-8444391e125e474cf8fa3d679d288dac2fa6da4c811ac1aa3de3044d02fd179a3</originalsourceid><addsrcrecordid>eNp9kM1Lw0AQxYMoWKv_gKc9ekm6X0024KWmHxaKFlrPy7A7KVvSpO6mSv97U6JXTzO8eW_g_aLokdGEUZaO9gkYDwmnXCY0S-hYXUUDpjIVSyrT626nWRqnQvDb6C6EPaVsnCoxiLBoDkfwLjQ1aUrC1DyeTxdkPduOii2B2vbSZL3801xNNufQ4sEZsmlh5-rdJfmG39WZTB3s6iagJS8eIbSkgNqgv49uSqgCPvzOYfQxn22L13j1vlgWk1VsGM95rKSUImfI-BhlJk2pShA2zXLLlbJgeAmpBWkUY2AYdDcUVEpLeWlZloMYRk_936NvPk8YWn1wwWBVQY3NKWjRwcryseC8s_LeanwTgsdSH707gD9rRvWFqd7rC1N9YapppjumXei5D2FX4suh18E47Bpa59G02jbuv_gPIz18Mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3101795322</pqid></control><display><type>article</type><title>Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer</title><source>Elsevier ScienceDirect Journals</source><creator>Bin, Ji ; Wenjia, Li ; Wan, Wang ; Kaiyin, Min ; Bowen, Yang ; Qichang, Wan ; Junzhi, Liu ; Shi, Gao</creator><creatorcontrib>Bin, Ji ; Wenjia, Li ; Wan, Wang ; Kaiyin, Min ; Bowen, Yang ; Qichang, Wan ; Junzhi, Liu ; Shi, Gao</creatorcontrib><description>The purpose of this study was to compare the performance of 18F-FAPI PET/CT and 18F-FDG PET/CT in systemic staging of newly diagnosed breast cancer.
Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both 18F-FAPI and 18F-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard.
38 patients were included. The overall upstaging rate was 47.4% for 18F-FAPI PET/CT (18/38) and 34.2% for 18F-FDG PET/CT (13/38). The rate of distant metastases disclosed by 18F-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly different from that of 18F-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly higher than that of 18F-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P < 0.001)] and distant metastases [98.1% (51/52) vs 67.3% (35/52), (P < 0.001)].
18F-FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer, in a rate higher than 18F-FDG PET/CT. The significantly higher lesion-based sensitivity in unsuspected metastases implies a future role of 18F-FAPI PET/CT in evaluation of metastatic disease burden.</description><identifier>ISSN: 1076-6332</identifier><identifier>ISSN: 1878-4046</identifier><identifier>EISSN: 1878-4046</identifier><identifier>DOI: 10.1016/j.acra.2024.07.058</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>18F-FAPI PET/CT ; 18F-FDG PET/CT ; Breast cancer ; Sensitivity ; Systemic staging</subject><ispartof>Academic radiology, 2025-01, Vol.32 (1), p.50-57</ispartof><rights>2024 The Association of University Radiologists</rights><rights>Copyright © 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1292-8444391e125e474cf8fa3d679d288dac2fa6da4c811ac1aa3de3044d02fd179a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1076633224005634$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Bin, Ji</creatorcontrib><creatorcontrib>Wenjia, Li</creatorcontrib><creatorcontrib>Wan, Wang</creatorcontrib><creatorcontrib>Kaiyin, Min</creatorcontrib><creatorcontrib>Bowen, Yang</creatorcontrib><creatorcontrib>Qichang, Wan</creatorcontrib><creatorcontrib>Junzhi, Liu</creatorcontrib><creatorcontrib>Shi, Gao</creatorcontrib><title>Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer</title><title>Academic radiology</title><description>The purpose of this study was to compare the performance of 18F-FAPI PET/CT and 18F-FDG PET/CT in systemic staging of newly diagnosed breast cancer.
Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both 18F-FAPI and 18F-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard.
38 patients were included. The overall upstaging rate was 47.4% for 18F-FAPI PET/CT (18/38) and 34.2% for 18F-FDG PET/CT (13/38). The rate of distant metastases disclosed by 18F-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly different from that of 18F-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly higher than that of 18F-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P < 0.001)] and distant metastases [98.1% (51/52) vs 67.3% (35/52), (P < 0.001)].
18F-FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer, in a rate higher than 18F-FDG PET/CT. The significantly higher lesion-based sensitivity in unsuspected metastases implies a future role of 18F-FAPI PET/CT in evaluation of metastatic disease burden.</description><subject>18F-FAPI PET/CT</subject><subject>18F-FDG PET/CT</subject><subject>Breast cancer</subject><subject>Sensitivity</subject><subject>Systemic staging</subject><issn>1076-6332</issn><issn>1878-4046</issn><issn>1878-4046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9kM1Lw0AQxYMoWKv_gKc9ekm6X0024KWmHxaKFlrPy7A7KVvSpO6mSv97U6JXTzO8eW_g_aLokdGEUZaO9gkYDwmnXCY0S-hYXUUDpjIVSyrT626nWRqnQvDb6C6EPaVsnCoxiLBoDkfwLjQ1aUrC1DyeTxdkPduOii2B2vbSZL3801xNNufQ4sEZsmlh5-rdJfmG39WZTB3s6iagJS8eIbSkgNqgv49uSqgCPvzOYfQxn22L13j1vlgWk1VsGM95rKSUImfI-BhlJk2pShA2zXLLlbJgeAmpBWkUY2AYdDcUVEpLeWlZloMYRk_936NvPk8YWn1wwWBVQY3NKWjRwcryseC8s_LeanwTgsdSH707gD9rRvWFqd7rC1N9YapppjumXei5D2FX4suh18E47Bpa59G02jbuv_gPIz18Mw</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Bin, Ji</creator><creator>Wenjia, Li</creator><creator>Wan, Wang</creator><creator>Kaiyin, Min</creator><creator>Bowen, Yang</creator><creator>Qichang, Wan</creator><creator>Junzhi, Liu</creator><creator>Shi, Gao</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202501</creationdate><title>Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer</title><author>Bin, Ji ; Wenjia, Li ; Wan, Wang ; Kaiyin, Min ; Bowen, Yang ; Qichang, Wan ; Junzhi, Liu ; Shi, Gao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1292-8444391e125e474cf8fa3d679d288dac2fa6da4c811ac1aa3de3044d02fd179a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>18F-FAPI PET/CT</topic><topic>18F-FDG PET/CT</topic><topic>Breast cancer</topic><topic>Sensitivity</topic><topic>Systemic staging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bin, Ji</creatorcontrib><creatorcontrib>Wenjia, Li</creatorcontrib><creatorcontrib>Wan, Wang</creatorcontrib><creatorcontrib>Kaiyin, Min</creatorcontrib><creatorcontrib>Bowen, Yang</creatorcontrib><creatorcontrib>Qichang, Wan</creatorcontrib><creatorcontrib>Junzhi, Liu</creatorcontrib><creatorcontrib>Shi, Gao</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Academic radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bin, Ji</au><au>Wenjia, Li</au><au>Wan, Wang</au><au>Kaiyin, Min</au><au>Bowen, Yang</au><au>Qichang, Wan</au><au>Junzhi, Liu</au><au>Shi, Gao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer</atitle><jtitle>Academic radiology</jtitle><date>2025-01</date><risdate>2025</risdate><volume>32</volume><issue>1</issue><spage>50</spage><epage>57</epage><pages>50-57</pages><issn>1076-6332</issn><issn>1878-4046</issn><eissn>1878-4046</eissn><abstract>The purpose of this study was to compare the performance of 18F-FAPI PET/CT and 18F-FDG PET/CT in systemic staging of newly diagnosed breast cancer.
Breast cancer patients with initial clinical stage IIB-IIIC who have consequently underwent both 18F-FAPI and 18F-FDG PET/CT from June 2022 to June 2023 were retrospectively analyzed. New clinical stage was assigned to each patient if unsuspected level III axillary and extraaxillary regional lymph node metastases (URNM) and/or distant metastases were disclosed after PET/CT. Sensitivity for both tests was calculated on patient basis and lesion basis using histology or follow-up imaging as reference standard.
38 patients were included. The overall upstaging rate was 47.4% for 18F-FAPI PET/CT (18/38) and 34.2% for 18F-FDG PET/CT (13/38). The rate of distant metastases disclosed by 18F-FAPI PET/CT was 5.5% in stage IIB patients, 30% in stage IIIA patients, 50% in stage IIIB patients, and 75% in stage IIIC patients. On patent-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly different from that of 18F-FDG PET/CT in detecting URNM [100% (13/13) vs 53.8% (7/13), (P = 0.031)], but not for distant metastases [100% (10/10) vs 90% (9/10), (P = 1.000)]. On lesion-based analysis, the sensitivity of 18F-FAPI PET/CT was significantly higher than that of 18F-FDG PET/CT in detecting URNM [97.6% (41/42) vs 52.4% (22/42), (P < 0.001)] and distant metastases [98.1% (51/52) vs 67.3% (35/52), (P < 0.001)].
18F-FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer, in a rate higher than 18F-FDG PET/CT. The significantly higher lesion-based sensitivity in unsuspected metastases implies a future role of 18F-FAPI PET/CT in evaluation of metastatic disease burden.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.acra.2024.07.058</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1076-6332 |
| ispartof | Academic radiology, 2025-01, Vol.32 (1), p.50-57 |
| issn | 1076-6332 1878-4046 1878-4046 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3101795322 |
| source | Elsevier ScienceDirect Journals |
| subjects | 18F-FAPI PET/CT 18F-FDG PET/CT Breast cancer Sensitivity Systemic staging |
| title | Comparison of 18F-FDG PET/CT and 18F-FAPI PET/CT in Systemic Staging of Newly Diagnosed Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T23%3A48%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%2018F-FDG%20PET/CT%20and%2018F-FAPI%20PET/CT%20in%20Systemic%20Staging%20of%20Newly%20Diagnosed%20Breast%20Cancer&rft.jtitle=Academic%20radiology&rft.au=Bin,%20Ji&rft.date=2025-01&rft.volume=32&rft.issue=1&rft.spage=50&rft.epage=57&rft.pages=50-57&rft.issn=1076-6332&rft.eissn=1878-4046&rft_id=info:doi/10.1016/j.acra.2024.07.058&rft_dat=%3Cproquest_cross%3E3101795322%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3101795322&rft_id=info:pmid/&rft_els_id=S1076633224005634&rfr_iscdi=true |